| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2527578 | Clinical Therapeutics | 2012 | 13 Pages |
Abstract
A tigecycline dosage of â¼1.2 mg/kg q12h may represent the most appropriate dosage for subsequent evaluation in Phase III clinical trials in children aged 8 to 11 years with selected serious bacterial infections. ClinicalTrials.gov identifier: NCT00488345.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Jay MD, PhD, Sylvie PhD, Jean Li MS, Ivana MD, Nathalie MD, C. Angel MS, Joan PharmD, PhD,